A vaccine manufacturer’s approach to address medical needs related to seasonal and pandemic influenza viruses
Open Access
- 1 November 2008
- journal article
- review article
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 2 (6) , 251-260
- https://doi.org/10.1111/j.1750-2659.2008.00054.x
Abstract
Vaccination is considered to be one of the most effective tools to decrease morbidity as well as mortality caused by influenza viruses.Keywords
This publication has 42 references indexed in Scilit:
- Mitigation Measures for Pandemic Influenza in Italy: An Individual Based Model Considering Different ScenariosPLOS ONE, 2008
- Broad Clade 2 Cross-Reactive Immunity Induced by an Adjuvanted Clade 1 rH5N1 Pandemic Influenza VaccinePLOS ONE, 2008
- Cross-Protection against Lethal H5N1 Challenge in Ferrets with an Adjuvanted Pandemic Influenza VaccinePLOS ONE, 2008
- Strategies for mitigating an influenza pandemicNature, 2006
- Recent changes among human influenza virusesVirus Research, 2004
- Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic useVirus Research, 2004
- Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983Published by Elsevier ,2004
- Ten Years of Experience with the Trivalent Split-Influenza Vaccine, Fluarix???Clinical Drug Investigation, 2002
- Kinetics of humoral antibody response to trivalent inactivated split influenza vaccine in subjects previously vaccinated or vaccinated for the first timeVaccine, 1996
- Antigenic and Genetic Characterization of the Haemagglutinins of Recent Cocirculating Strains of Influenza B VirusJournal of General Virology, 1992